Market starts off 2023 with a bang, rebounds for winning week. Plus, a new Alzheimer’s drug approval. 1/6/23 episode artwork

EPISODE · Jan 6, 2023 · 22 MIN

Market starts off 2023 with a bang, rebounds for winning week. Plus, a new Alzheimer’s drug approval. 1/6/23

from CNBC's "Fast Money" · host CNBC

Stocks rally Friday after a seemingly ‘goldilocks’ jobs report, with consumer-leveraged stocks among the biggest winners. Plus, an exclusive with the EISAI US CEO - which worked with Biogen on the FDA’s approval of its Alzheimer’s treatment that slowed cognitive decline in a clinical trial. Hosted by Simplecast, an AdsWizz company. See https://pcm.adswizz.com for information about our collection and use of personal data for advertising.

Episode metadata supplied by the publisher feed · Published Jan 6, 2023

Embed this episode

Stocks rally Friday after a seemingly ‘goldilocks’ jobs report, with consumer-leveraged stocks among the biggest winners. Plus, an exclusive with the EISAI US CEO - which worked with Biogen on the FDA’s approval of its Alzheimer’s treatment that slowed cognitive decline in a clinical trial.

Distinct summary based on available episode metadata or transcript content.

Ready to play

Market starts off 2023 with a bang, rebounds for winning week. Plus, a new Alzheimer’s drug approval. 1/6/23

0:00 22:16

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of CNBC's "Fast Money"?

This episode is 22 minutes long.

When was this CNBC's "Fast Money" episode published?

This episode was published on January 6, 2023.

Can I download this CNBC's "Fast Money" episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!